Yazar "Basarali, Mustafa Kemal" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    A comparison of the effects of aggressive dose and conventional dose atorvastatin applications on IL-6 and NO levels in patients with acute myocardial infarction
    (ACADEMIC JOURNALS, 2011) Basarali, Mustafa Kemal; Buyukbas, Sadik; Yazar, Hayrullah; Kiyici, Aysel; Kayrak, Mehmet; Ulgen, Siddik
    High dose statin medication in acute coronary syndrome cases is a therapy which lowers mortality and morbidity rates. Interleukin-6 (IL-6) is produced in higher amounts in acute myocardial infarction (MI) and facilitates myocardial damage. However, secretion of nitric oxide (NO) is depleted. We aimed to compare the effects of conventional dose (10-40 mg/day) and aggressive dose (80 mg/day) atorvastatin medications on IL-6 and NO levels in patients with primary percutaneous transluminal coronary angioplasty (PTCA) intervention after acute MI. 50 patients (8 females, 42 males) with the diagnosis of acute MI with ST segment elevation enrolled to the study. Primary PTCA intervention was performed on these patients and consequently either conventional dose (10 to 40 mg/day) or aggressive dose (80 mg/day) atorvastatin medications were given to the patients. Three months later, plasma IL-6 and NO levels were determined and alterations in the groups were evaluated. IL-6 levels decreased from 24.34 +/- 12.04 to 11.40 +/- 5.79 pg/ml and from 29.62 +/- 17.38 to 12.51 +/- 8.95 pg/ml in conventional dose and aggressive dose regimens respectively (p<0.001). However, NO concentrations increased from 22.90 +/- 8.24 to 31.70 +/- 7.56 mu M in conventional dose and from 19.37 +/- 5.60 mu M to 34.15 +/- 9.60 mu M in aggressive dose groups (p < 0.001). The effects of aggressive dose atorvastatin medication on IL-6 and NO levels were similar to conventional dose application in cases with ST segment elevation acute MI.
  • Küçük Resim Yok
    Öğe
    EFFECTS OF REPEATED SUPRAMAXIMAL EXERCISES ON PLASMA ADIPONECTIN, IL-6 AND TNF-alpha LEVELS
    (SPRINGER TOKYO, 2009) Gergerlioglu, Hasan Serdar; Gokbel, Hakki; Okudan, Nilsel; Gul, Ibrahim; Belviranli, Muaz; Basarali, Mustafa Kemal
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Plasma concentrations of soluble CD40 ligand in smokers with acute myocardial infarction: a pilot study
    (SPRINGER, 2011) Kayrak, Mehmet; Bacaksiz, Ahmet; Ulgen, Mehmet S.; Vatankulu, Mehmet Akif; Zengin, Kadriye; Ayhan, Selim S.; Basarali, Mustafa Kemal
    Coronary artery disease (CAD) is believed to be the single leading cause of death in both men and women in the world. Smoking is the most important risk factor for CAD. Smoking increases platelet aggregation and thrombus formation. CD40 ligand (CD40L) is a transmembrane glycoprotein derived from activated platelets. It participates in thrombus formation during the acute phase of acute myocardial infarction (MI). Elevation of CD40L identifies the patients who are at highest risk for cardiac events and who are likely to benefit from treatment with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists. The purpose of this study was to evaluate levels of CD40L in smokers with acute MI. Fifty-seven patients with acute MI were enrolled in this study. Thirty-one smokers were compared with 26 non-smokers. Soluble CD40L level in the plasma was determined by a standard enzyme-linked immunosorbent assay. Circulating levels of CD40L were higher in the smokers' group. Smokers with acute MI may have increased risk for thrombotic complications during acute MI, and optimal antiaggregant therapy should be administered.